{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:08:40Z","timestamp":1776276520658,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40744-019-0148-4","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T10:05:15Z","timestamp":1551780315000},"page":"207-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Persistence, Discontinuation, and Switching Patterns of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients in the United States"],"prefix":"10.1007","volume":"6","author":[{"given":"Theresa","family":"Hunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"key":"148_CR1","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","volume":"1","author":"J Sieper","year":"2015","unstructured":"Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1:15013.","journal-title":"Nat Rev Dis Primers"},{"key":"148_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/ard.2009.116764","volume":"69","author":"A Boonen","year":"2010","unstructured":"Boonen A, Brinkhuizen T, Landewe R, et al. Impact of ankylosing spondylitis on sick leave, presenteeism, and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis. 2010;69:1123\u20138.","journal-title":"Ann Rheum Dis"},{"key":"148_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1586\/14737167.2014.957679","volume":"14","author":"K Kotsis","year":"2014","unstructured":"Kotsis K, Voulgari PV, Dross AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoeconomic Outcomes Res. 2014;14:857\u201372.","journal-title":"Expert Rev Pharmacoeconomic Outcomes Res"},{"issue":"9313","key":"148_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial. Lancet. 2002;359(9313):1187\u201393.","journal-title":"Lancet"},{"issue":"11","key":"148_CR5","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230\u20136.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"148_CR6","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136\u201346.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"148_CR7","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402\u201312.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"148_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73(1):39\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"148_CR9","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"148_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/acr.22708","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendation for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(2):151\u201366.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"148_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rodevand E, Koldingsnes W, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70:157\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"148_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","volume":"29","author":"M Bonafede","year":"2012","unstructured":"Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664\u201374.","journal-title":"Adv Ther"},{"issue":"4","key":"148_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/cer-2017-0076","volume":"7","author":"J Walsh","year":"2018","unstructured":"Walsh J, Adejoro O, Chastek B, Park Y. Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Effect Res. 2018;7(4):369\u201380.","journal-title":"J Comp Effect Res"},{"key":"148_CR14","unstructured":"Bekele D, Cheng E, Geier C, Ganuthula K, Walsh J, Dubreuil M, et al. Tumor necrosis factor inhibitor persistence and reasons for discontinuation in US veterans with axial spondyloarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https:\/\/acrabstracts.org\/abstract\/tumor-necrosis-factor-inhibitor-persistence-and-reasons-for-discontinuation-in-us-veterans-with-axial-spondyloarthritis\/. Accessed January 2, 2019."},{"key":"148_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:94.","journal-title":"Arthritis Res Ther"},{"key":"148_CR16","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acr.20258","volume":"62","author":"LE Kristensen","year":"2010","unstructured":"Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res. 2010;62:1362\u20139.","journal-title":"Arthritis Care Res"},{"key":"148_CR17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krigh NS, Tarp U, Manilo N, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO registry. Ann Rheum. 2013;72:1149\u201355.","journal-title":"Ann Rheum"},{"issue":"4","key":"148_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3899\/jrheum.170166","volume":"45","author":"M Hebeisen","year":"2018","unstructured":"Hebeisen M, Neunschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi L, Zufferey P, et al. Response to tumor necrosis inhibition in male and female patients with ankylosing spondylitis: data from a Swiss Cohort. J Rheumatol. 2018;45(4):506\u201312.","journal-title":"J Rheumatol"},{"issue":"5","key":"148_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/1529-0131(200110)45:5<424::AID-ART361>3.0.CO;2-7","volume":"45","author":"JH Barlow","year":"2001","unstructured":"Barlow JH, Wright CC, Williams B, Keta A. Work disability among people with ankylosing spondylitis. Arthritis Care Res. 2001;45(5):424\u20139.","journal-title":"Arthritis Care Res"},{"key":"148_CR20","first-page":"204","volume":"63","author":"KM Fagerli","year":"2011","unstructured":"Fagerli KM, Lie E, Heiberg MS, et al. Predictors of ASDAS major improvement in patients with ankylosing spondylitis receiving their first TNF inhibitor. Results from a longitudinal observational study. Arthritis Rheum. 2011;63:204\u20135.","journal-title":"Arthritis Rheum"},{"key":"148_CR21","first-page":"641","volume":"30","author":"S Ramiro","year":"2012","unstructured":"Ramiro S, Machado P, Roque R, et al. Predictive factors of response at 12\u00a0weeks in patients with ankylosing spondylitis starting biological therapies\u2014results from the Portuguese register\u2014Rheuma.Pt. Clin Exp Rheumatol. 2012;30:641\u20132.","journal-title":"Clin Exp Rheumatol"},{"key":"148_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-019-0148-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-019-0148-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-019-0148-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:39:41Z","timestamp":1724456381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-019-0148-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["148"],"URL":"https:\/\/doi.org\/10.1007\/s40744-019-0148-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"2 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}